Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Laurini

Showing results (51-60 of 118) with videos related to

Pageof 12
Sort By:
Journal of Medicinal Chemistry|August 24, 2012
Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptorChristina Meyer, Dirk Schepmann, Shuichi Yanagisawa, et al.
European Journal of Medicinal Chemistry|April 29, 2008
Substituted benzo[d]oxazol-2(3H)-one derivatives with preference for the sigma1 binding siteDaniele Zampieri, Maria Grazia Mamolo, Erik Laurini, et al.
European Journal of Medicinal Chemistry|July 2, 2016
Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligandsDaniele Zampieri, Luciano Vio, Maurizio Fermeglia, et al.
Molecules (Basel, Switzerland)|May 4, 2026
Benchmarking OPLS-AA and OpenFF for HDI-PEG Thermoplastic Polyurethanes with Varying Soft-Segment LengthFrancesco Blasina, Tetiana Bubon, Francesco Cristiano, et al.
Bioorganic & Medicinal Chemistry|May 27, 2009
Antimycobacterial activity of new 3,5-disubstituted 1,3,4-oxadiazol-2(3H)-one derivatives. Molecular modeling investigationsDaniele Zampieri, Maria Grazia Mamolo, Erik Laurini, et al.
Acta Crystallographica. Section D, Structural Biology|April 29, 2026
Gaining insights into MmpL3: combining structural and computational approaches to unlock transport and inhibitor-binding mechanismsSatoshi Murakami, Domenico Marson, Eiki Yamashita, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 23, 2022
Some things old, new and borrowed: Delivery of dabrafenib and vemurafenib to melanoma cells via self-assembled nanomicelles based on an amphiphilic dendrimerMaria Russi, Rachele Valeri, Domenico Marson, et al.
Molecular Oncology|March 18, 2015
Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)Lara Brambilla, Davide Genini, Erik Laurini, et al.
Molecular Pharmaceutics|July 12, 2013
Impact of siRNA overhangs for dendrimer-mediated siRNA delivery and gene silencingPaola Posocco, Xiaoxuan Liu, Erik Laurini, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2020
Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial ActivityMichele Tonelli, Anna Sparatore, Nicoletta Basilico, et al.
Pageof 12

Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
Journal of Medicinal Chemistry|August 24, 2012
Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptorChristina Meyer, Dirk Schepmann, Shuichi Yanagisawa, et al.
European Journal of Medicinal Chemistry|April 29, 2008
Substituted benzo[d]oxazol-2(3H)-one derivatives with preference for the sigma1 binding siteDaniele Zampieri, Maria Grazia Mamolo, Erik Laurini, et al.
European Journal of Medicinal Chemistry|July 2, 2016
Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligandsDaniele Zampieri, Luciano Vio, Maurizio Fermeglia, et al.
Molecules (Basel, Switzerland)|May 4, 2026
Benchmarking OPLS-AA and OpenFF for HDI-PEG Thermoplastic Polyurethanes with Varying Soft-Segment LengthFrancesco Blasina, Tetiana Bubon, Francesco Cristiano, et al.
Bioorganic & Medicinal Chemistry|May 27, 2009
Antimycobacterial activity of new 3,5-disubstituted 1,3,4-oxadiazol-2(3H)-one derivatives. Molecular modeling investigationsDaniele Zampieri, Maria Grazia Mamolo, Erik Laurini, et al.
Acta Crystallographica. Section D, Structural Biology|April 29, 2026
Gaining insights into MmpL3: combining structural and computational approaches to unlock transport and inhibitor-binding mechanismsSatoshi Murakami, Domenico Marson, Eiki Yamashita, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 23, 2022
Some things old, new and borrowed: Delivery of dabrafenib and vemurafenib to melanoma cells via self-assembled nanomicelles based on an amphiphilic dendrimerMaria Russi, Rachele Valeri, Domenico Marson, et al.
Molecular Oncology|March 18, 2015
Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)Lara Brambilla, Davide Genini, Erik Laurini, et al.
Molecular Pharmaceutics|July 12, 2013
Impact of siRNA overhangs for dendrimer-mediated siRNA delivery and gene silencingPaola Posocco, Xiaoxuan Liu, Erik Laurini, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2020
Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial ActivityMichele Tonelli, Anna Sparatore, Nicoletta Basilico, et al.
Pageof 12